Yael Weiss

Yael Weiss

Company: Ultragenyx

Job title: Vice President Business Development


Symptomatic vs Genetic Disease Modifying Treatments 9:10 am

Most industry portfolios reflect either a strategic balance between, or unitary commitment to either small molecule or genetic modalities for engaging targets involved in the biological processes implicated in rare diseases of the central nervous system. This panel will explore key strategic, technical, and scientific considerations shaping these decisions. • How can we assess benefit/risk…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.